KEAP1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Results of western blotting showed that AT56 treatment decreased the expression of ferroptosis-associated transcription factor NRF2, increased the expression of KEAP1, the negative regulator of NRF2, in PTCL cells in a dose-dependent manner (Fig. 6a).